Skip to main content
SpringerLink
Log in

Posaconazole prophylaxis cost beneficial in high-risk patients

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2014 US dollars

Reference

  • Cho SY, et al. Cost-Benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-Risk Hematologic Patients: A Propensity Score-Matched Analysis. Clinical Therapeutics : 15 Jul 2015. Available from: URL: http://doi.org/10.1016/j.clinthera.2015.06.014

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Posaconazole prophylaxis cost beneficial in high-risk patients. PharmacoEcon Outcomes News 733, 28 (2015). https://doi.org/10.1007/s40274-015-2329-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-015-2329-x

Search

Navigation